Circulating Lp-PLA2 activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapy

[1]  M. Cesari,et al.  Proinflammatory cytokines, aging, and age-related diseases. , 2013, Journal of the American Medical Directors Association.

[2]  J. Chae,et al.  Effect of age on atherogenicity of LDL and inflammatory markers in healthy women. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  S. Kritchevsky,et al.  Total and abdominal adiposity are associated with inflammation in older adults using a factor analysis approach. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  J. H. Lee,et al.  Circulating and PBMC Lp-PLA2 Associate Differently with Oxidative Stress and Subclinical Inflammation in Nonobese Women (Menopausal Status) , 2012, PloS one.

[5]  J. H. Lee,et al.  Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome. , 2011, Atherosclerosis.

[6]  A. Newman,et al.  Inflammatory markers in population studies of aging , 2011, Ageing Research Reviews.

[7]  E. Izkhakov,et al.  [Lipoprotein associated phospholipase A2]. , 2011, Harefuah.

[8]  I. Vega-Naredo,et al.  Differential inflammatory responses in aging and disease: TNF-alpha and IL-6 as possible biomarkers. , 2010, Free radical biology & medicine.

[9]  S. Johnston,et al.  Association of Carotid Plaque Lp-PLA2 with Macrophages and Chlamydia pneumoniae Infection among Patients at Risk for Stroke , 2010, PloS one.

[10]  E. Rimm,et al.  Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. , 2010, The American journal of clinical nutrition.

[11]  J. Li,et al.  OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. , 2010, Cardiovascular research.

[12]  C. Stefanadis,et al.  Lipids in Health and Disease Lipoprotein-associated Phospholipase a 2 (lp-pla 2 ) Activity, Platelet-activating Factor Acetylhydrolase (paf-ah) in Leukocytes and Body Composition in Healthy Adults , 2022 .

[13]  A. Frasheri,et al.  Small, dense low‐density lipoproteins (LDL) are predictors of cardio‐ and cerebro‐vascular events in subjects with the metabolic syndrome , 2009, Clinical endocrinology.

[14]  Ping Zhang,et al.  Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development , 2008, Nature Medicine.

[15]  J. H. Lee,et al.  Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. , 2008, The American journal of clinical nutrition.

[16]  B. Psaty,et al.  Distribution and Correlates of Lipoprotein‐Associated Phospholipase A2 in an Elderly Cohort: The Cardiovascular Health Study , 2008, Journal of the American Geriatrics Society.

[17]  M. Hanefeld,et al.  The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. , 2008, Journal of the American College of Cardiology.

[18]  J. Ordovás,et al.  Atherogenecity of LDL and Unfavorable Adipokine Profile in Metabolically Obese, Normal‐weight Woman , 2008, Obesity.

[19]  J. Manson,et al.  Postmenopausal Cardiovascular Risk Lipoprotein-Associated Phospholipase A 2, Hormone Use, and the Risk of Ischemic Stroke in Postmenopausal Women , 2022 .

[20]  J. Carlquist,et al.  Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target , 2007, Expert review of molecular diagnostics.

[21]  R. Wilensky,et al.  Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. , 2007, Atherosclerosis.

[22]  G. Berglund,et al.  The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. , 2007, Atherosclerosis.

[23]  L. Lerman,et al.  Lipoprotein-Associated Phospholipase A2 Is an Independent Marker for Coronary Endothelial Dysfunction in Humans , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[24]  M. Rizzo,et al.  Low-density lipoprotein size and cardiovascular risk assessment. , 2006, QJM : monthly journal of the Association of Physicians.

[25]  M. Elisaf,et al.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. , 2005, Clinical chemistry.

[26]  E. Boerwinkle,et al.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. , 2005, Archives of internal medicine.

[27]  H. Brenner,et al.  Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. , 2005, Atherosclerosis.

[28]  A. Hofman,et al.  Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study , 2005, Circulation.

[29]  D. Jacobs,et al.  Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults: The CARDIA Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[30]  E. Brilakis,et al.  Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. , 2005, European heart journal.

[31]  C. Meisinger,et al.  Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany , 2004, Circulation.

[32]  T. Montine,et al.  Oxidized low-density lipoprotein is present in astrocytes surrounding cerebral infarcts and stimulates astrocyte interleukin-6 secretion. , 2004, The American journal of pathology.

[33]  B. Pedersen,et al.  Age-related inflammatory cytokines and disease. , 2003, Immunology and allergy clinics of North America.

[34]  J. Goudevenos,et al.  Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. , 2002, Journal of lipid research.

[35]  H. Sinzinger,et al.  The isoprostane 8-epi-PGF2α is a valuable indicator of oxidative injury in human heart valves , 2001 .

[36]  H. Sinzinger,et al.  The isoprostane 8-epi-PGF(2alpha) is a valuable indicator of oxidative injury in human heart valves. , 2001, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[37]  D. Papanicolaou,et al.  Interleukin-6: the endocrine cytokine. , 2000 .

[38]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.

[39]  G. FitzGerald,et al.  Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[40]  T. Jones.  Interleukin‐6 an endocrine cytokine , 1994, Clinical endocrinology.